Zenas BioPharma Eyes FDA BLA After 56% IgG4-RD Flare Reduction, Cash to 2029
Zenas BioPharma achieved a 56% reduction in IgG4-RD flares in its Phase 3 INDIGO trial, with a BLA submission to FDA slated this quarter and an MAA filing to EMA in H2 2026. Recent public offerings and debt financing extend its cash runway into 2029.
1. Clinical and Regulatory Milestones
Zenas reported that obexelimab met primary and all four key secondary endpoints in its Phase 3 INDIGO trial, achieving a 56% reduction in IgG4-Related Disease flares versus placebo over 52 weeks. The company plans to submit a Biologics License Application to FDA this quarter and file a Marketing Authorization Application with EMA in the second half of 2026, with data set for an oral presentation at EULAR 2026.
2. Pipeline Progress
Enrollment in the global Phase 2 SunStone SLE trial is complete, with topline results expected in Q4 2026. Zenas has dosed the first subject in the Phase 1 trial of ZB021 and anticipates initial clinical data by year-end, followed by a North American proof-of-concept in psoriasis in 2027. Meanwhile, global Phase 3 PriMroSe and Monarch trials of orelabrutinib in PPMS and naSPMS continue.
3. Financing and Cash Runway
Zenas completed public equity offerings and entered into debt financing this quarter, extending its cash runway into 2029 to support ongoing development, regulatory submissions, and potential commercialization of obexelimab.